Story perspectives

Study Links Proton Pump Inhibitors to Poorer Cancer Survival

11/6/2025

46 9

Summary

Story summary

Proton pump inhibitors used by breast cancer patients were linked to poorer survival and a 36% higher risk of severe side effects in a major international study analyzing 23,000 patients led by the University of South Australia and Flinders University.
Beta-blockers and ACE inhibitors increased adverse events but did not affect survival.
Statins and metformin showed no significant impact on outcomes.
The study emphasizes considering all medications in cancer care.

1 of 1

Story summary

Proton pump inhibitors used by breast cancer patients were linked to poorer survival and a 36% higher risk of severe side effects in a major international study analyzing 23,000 patients led by the University of South Australia and Flinders University.
Beta-blockers and ACE inhibitors increased adverse events but did not affect survival.
Statins and metformin showed no significant impact on outcomes.
The study emphasizes considering all medications in cancer care.